Thomas Cook , SOTC Partner with Cricket Australia for Border-Gavaskar Trophy

Key Takeaways from Thomas Cook and SOTC Partnership with Cricket Australia:

• Thomas Cook India Ltd has announced its partnership with SOTC Travel to be the exclusive holiday package provider for Cricket Australia for the Border-Gavaskar Trophy FY25.
• The five Test match series will start from November 22, 2024 and end on January 7, 2025. In this, the two crucial games to be played here are the ones at the Melbourne Cricket Ground as well as the Gabba in Brisbane.
• Thomas Cook and SOTC will develop marketing promotions along with the booking services that will have match tickets and travel arrangements for all kinds of target audiences .
• Group and tour packages will be structured according to different locations, including Sydney, Cairns, Gold Coast, Perth, Melbourne, and Adelaide.

Other significant matches that will feature include a Boxing Day Test at the Melbourne Cricket Ground, games at the Gabba in Brisbane, and Sydney Cricket Ground.

Thomas Cook and SOTC would develop products, marketing promotions, and booking services comprising match tickets and other forms of travel to cater for diversified audiences.

Thomas Cook and SOTC have packaged various group and customised tour packages around the five Test matches. These are definitely going to be in hot demand, primarily across Sydney, Cairns, Gold Coast, Perth, Melbourne, and Adelaide.

About Thomas Cook India Limited:

Thomas Cook (India) Limited (TCIL), founded in 1881, is a leading travel company in India, offering foreign exchange, corporate travel, MICE, leisure travel, visa services, and more. The group operates several strong brands worldwide and has a wide network across 28 countries on five continents.

TCIL has been rewarding its excellence in travel industry MICE recognition, risk management, and innovation. New accolades include winning the MICE Travel Agency award at the Economic Times Awards 2024 and winning Best Tour Operator Award at India Travel Awards North 2023.

The rating firm, CRISIL, has given its rating on the strong financial stability of TCIL, affirming its long-term rating at 'CRISIL AA-/Positive' and a short-term rating of 'CRISIL A1+'.

About SOTC Travel Limited:

SOTC Travel Limited is a subsidiary of Fairfax Financial Holdings but operates under its Indian-listed parent company, Thomas Cook (India) Limited, TCIL. SOTC is one of the major travel and tourism companies which provide services in Leisure Travel, Incentive Travel, as well as Business Travel. Established in 1949, SOTC has a legacy of 75 years and has escorted millions of travellers to destinations across the globe. The company takes immense pride in knowing that it understands the requirements of Indian travellers better than anybody else.

Key Takeaways from Krsnaa Diagnostics and Apulki Healthcare Partnership:

• Krsnaa Diagnostics has joined hands with Apulki Healthcare in an investment tie-up to form cancer and cardiac care hospitals in India.
• Through more than 30 years of being an exclusive diagnostics partner for Apulki healthcare, Krsnaa has consolidated its stance in the oncology and cardiac diagnostics market.
• The partnership will begin with the two 125 plus bed-capacity hospitals in Pune and Mumbai, then later expand into other metropolitan cities with more hospitals.
• Krsnaa and Apulki will offer round-the-clock comprehensive diagnostic services including MRI, PET CT, Cardiac CT, and advance pathology.
• A collaboration to deliver highest international standards in diagnostics for better prognosis with regard to early detection, treatment accuracy, and survival rates for cancer and cardiac patients.

As part of this, Krsnaa diagnostics has been chosen as the exclusive diagnostics partner for over 30 years for all the cancer and cardiac hospitals of Apulki. This partnership would initiate in the first phase two hospitals in the regions of Pune and Mumbai with over 125 beds in every hospital, and more hospitals are to be initiated in other metropolitan regions.

Krsnaa and Apulki will be offering services 24/7 with MRI, PET CT, Cardiac CT, and Advanced Pathology. This partnership will work toward seamless, world-class diagnostic solutions for patients being treated for both cancer and the cardiac clinical treatments at large, to enhance early detection and treatment accuracy and survival through timely and precise diagnoses.

Commenting on the development, Kinjal Babariya, Director of Apulki Healthcare, said, “This powerful collaboration ensures we are uniquely poised to capitalize on opportunities faster and more efficiently than any other player in the market. With this partnership we are eliminating the barriers of fragmented healthcare by integrating diagnostics and treatment under one roof.”

About Krsnaa Diagnostics Limited:

Krsnaa Diagnostics Limited is India's fastest-growing provider of diagnostic services in Radiology and Pathology having grown from two radiology centers in 2011 to well over 2,900 centers across 18 states and union territories. By focusing on giving quality diagnostics at accessible and affordable costs, Krsnaa has been able to offer clinical excellence through teleradiology that would support evidence-based treatment nationwide. They utilize state-of-the-art technology, including a cloud-based PACS workflow, to deliver fast, accurate reports from highly qualified experts all over the world. The company offers excellent service with quick turnaround of reports and convenient consultations while being a first CAP-accredited lab in India as a public-private partnership and possessing the largest NABH-accredited tele-radiology hub in Pune.

Key takeaways from the Biocoin and Tabuk Pharma Agreement

• Biocon Limited has signed a licensing and supply agreement with Tabuk Pharmaceuticals to commercialise its GLP-1 products for diabetes and chronic weight management in the Middle East.
• Biocon will develop and manufacture the products, while Tabuk Pharmaceuticals will handle marketing, registration, import, and promotion in select Middle Eastern countries.
• The agreement includes provisions to expand into other GLP-1 products and an option for tech transfer to enable localised manufacturing in the future.

GLP-1 products are aimed at treating diabetes and chronic weight management in select countries within the Middle East region. 

Biocon will handle the development and manufacturing of the products, while Tabuk Pharmaceuticals will be responsible for marketing authorisation, registration, import, and promotion. The agreement also includes potential expansion to other GLP products, with an option for tech transfer for localised manufacturing in the future.

About GLP-1 Products 

Glucagon-like peptide-1 (GLP-1) medications are used to regulate blood sugar levels and aid in weight loss by enhancing insulin production, reducing glucagon secretion, and slowing gastric emptying. These physiological hormones improve glycaemic control and have been vital in managing diabetes.

This collaboration marks a significant step in improving access to affordable therapies for chronic conditions in the Middle East.

Commenting on the agreement, Siddharth Mittal, Chief Executive Officer and Managing Director, Biocon Ltd, said, “I am pleased to expand our partnership with Tabuk Pharmaceuticals, which paves the way for our vertically integrated, complex GLP1 formulations entry into Saudi Arabia and other countries in the region. The partnership is further validation of our concerted focus on GLPs and Peptides as future growth drivers. This is another important milestone for Biocon, reflecting our commitment to providing patients around the globe with affordable medications, by establishing a strong portfolio of products, either directly or through strategic partnerships.” 

Ismail Shehadah, Chief Executive Officer of Tabuk Pharmaceuticals, said, “We are excited to announce our partnership with Biocon that will enable us to deliver unique health solutions aimed at enhancing the well-being of people in Saudi Arabia and other countries we operate in. We are confident that this partnership supports our efforts to manufacture and localize a range of GLP-1 products in the region and strengthen our market leading position in the area of diabetes medications, in line with our strategy. This also stands as a commitment from our side to support the 2030 vision of Saudi Arabia through localizing specialty pharmaceutical products in the Kingdom.” 

About Biocon Limited 

Biocon Limited, listed on the stock exchange in 2004, is a global biopharmaceutical company focused on innovation. The company is dedicated to making advanced therapies for chronic conditions like diabetes, cancer, and autoimmune diseases more accessible and affordable. Biocon has introduced cutting-edge biologics, biosimilars, and small-molecule APIs in India and globally, including generic drugs in the U.S. and Europe. It is also working on developing new treatments in the field of immunotherapy. 

About Tabuk Pharmaceuticals 

Tabuk Pharmaceuticals, a prominent pharmaceutical company in Saudi Arabia, operates throughout the Middle East and North Africa (MENA) region. The company develops, manufactures, and distributes branded generic medicines and partners with international pharmaceutical companies to produce high-quality medicines at its facilities in Saudi Arabia. With over 2,400 employees, Tabuk Pharmaceuticals serves patients in 17 MENA countries and has plans to expand its presence further. Its manufacturing plants are located in Tabuk, Dammam, Sudan, and Algeria.

Key Takeaways from Netweb Technologies Award Win:

• Netweb Technologies India, received on September 26, an Intel Partner Award for Outstanding Growth in the Data Center & AI Group.
• With this award, Netweb reinforces its commitment to delivering AI-ready solutions and its "AI-First" strategy to help customers improve capabilities and simplify operations.
• The company provides sovereign AI cloud solutions by offering Make in India Servers so that it supports in propagating local innovation and development of technology.

This success is a recognition of the company's commitment to AI-ready solutions and towards an "AI-First" strategy that can help customers enhance their capabilities while reducing organisational complexity.

Apart from this, Netweb is now working towards developing a Private AI lab to help the nation's universities and research entities realise the power of AI for transformative change. The organisation also offers sovereign AI cloud solutions through its Make in India Servers.

Sanjay Lodha, CMD of Netweb Technologies commenting on the development said, "Our strategic partnership with Intel has been instrumental in our journey to deliver cutting-edge solutions that empower our customers to achieve advancements in AI, High-Performance Computing (HPC), storage, data centres, and private cloud infrastructures.”

About Netweb Technologies India Limited:

Netweb Technologies India Limited is an Indian-owned leader in High-end Computing Solutions (HCS). It combines innovative design with manufacturing capabilities to offer a broad range of products, including High-Performance Computing (HPC) systems, Private Cloud and Hyperconverged Infrastructure (HCI), AI systems, enterprise workstations, High-Performance Storage (HPS), Data Center servers, and enterprise-grade network switches. The offered solutions come with a complement of software and services that are supported by in-house PCB design centres, surface mounting technology facilities, and advanced manufacturing lines.

About Intel:

Intel is behind the technological innovations that make life better for everyone around the globe. Gordon Moore and Bob Noyce founded the company, and it made silicon the "Moore's Law" technology platform through ingenuity and process altered the industry forever. Inspired by "Moore's Law," Intel has continued its work in semiconductors and manufacturing with designs aimed at working through all of the important issues for its customers. As a cloud, network, edges, and various computing device architectures developer, Intel aims to unlock the potential of data to build a better future for all.